GeneDx Shares Jump 6.1% on Q4 Beat and Buy Upgrade
GeneDx posted Q4 revenue growth exceeding estimates, raised full-year guidance and triggered a 6.1% share surge on higher exome/genome testing volumes with improved reimbursement rates. Analysts upgraded to Buy as DCF forecasts target 25% CAGR, 10%-14% free cash flow margins, while management plans to triple its commercial footprint in 2026.
1. Q4 Earnings and Guidance Raise
GeneDx reported stronger-than-expected Q4 performance driven by a significant year-over-year increase in high-value exome and genome testing volumes. The company also cited meaningful improvements in insurance reimbursement rates and raised its full-year guidance, prompting a 6.1% rally in its share price.
2. Buy Rating and DCF Forecasts
Following the Q4 beat, analysts upgraded the stock to a Buy rating based on discounted cash flow models projecting a 25% compound annual growth rate and free cash flow margins expanding from 10% toward 14%. These forecasts reflect confidence in sustained revenue growth and margin improvement.
3. Commercial Footprint Expansion
Management outlined plans to nearly triple its commercial footprint in 2026, prioritizing market expansion and customer acquisition. This aggressive scaling strategy is intended to capture additional testing demand and support the projected growth trajectory through 2027.